{"id":19430,"date":"2019-11-08T15:21:42","date_gmt":"2019-11-08T14:21:42","guid":{"rendered":"http:\/\/semmelweis.hu\/english\/?p=19430"},"modified":"2022-10-19T10:21:03","modified_gmt":"2022-10-19T08:21:03","slug":"molecular-muscle-research-and-translational-topics-semmelweis-symposium-day-3-videos","status":"publish","type":"post","link":"https:\/\/semmelweis.hu\/english\/2019\/11\/molecular-muscle-research-and-translational-topics-semmelweis-symposium-day-3-videos\/","title":{"rendered":"Molecular muscle research and translational topics \u2013 Semmelweis Symposium Day 3 (+videos)"},"content":{"rendered":"

The closing day of Semmelweis Symposium focused on molecular muscle research and translational research based on basic research focusing on heart failure, regenerative medicine, fibrotic conditions and the inflammatory aspects of cardiovascular comorbidities. 14 lectures were distributed among four sessions. Report by Dr. Zolt\u00e1n Varga, senior research fellow of the Department of Pharmacology and Pharmacotherapy, one of the session leaders on Day 3.<\/strong><\/p>\n

The first session in the morning covered a number of topics related to heart failure. In his presentation, Professor Johannes Backs (University of Heidelberg, Germany) talked about the key role of inflammatory mechanisms in acute heart failure, presenting new therapeutic options for the treatment of Takotsubo cardiomyopathy and heart failure caused by sepsis.<\/p>\n

The presentation given by Dr. Nazha Hamdani (Ruhr Bochum University, Germany) introduced the results of the study of a new clinical entity, heart failure characterized by retained ejection fraction. This disease occurs mainly in patients suffering from obesity and other comorbidities and no treatment has been found yet. Based on Hamandi\u2019s findings, several factors, such as soluble guanylate cyclase, leading to inflammatory and oxidative tissue damage, may become new therapeutic targets in the targeted medicinal therapy of the future. The session\u2019s closing presentation by Professor Petar Seferovic (University of Belgrade, Serbia) showed the links between the basic research results previously presented and the results of the latest clinical trials. According to his report, several new drugs appear to be promising in treating the various clinical manifestations of heart failure, highlighting the latest papers on the positive clinical effects of sacubitril\/valsartan and SGLT2 inhibitors.<\/p>\n\n\n